Company news
Sionna Therapeutics, Inc. (NASDAQ:SION) news
Sionna Therapeutics, Inc. news releases on 6ix. Latest, Sep 14, 2026: Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination…
Press releases & updates
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
September 14, 2026
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
August 10, 2026
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
August 6, 2026
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
May 27, 2026
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
Sionna Therapeutics Reports First Quarter 2026 Financial Results
May 12, 2026
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
April 27, 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
April 7, 2026
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 1, 2026
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
February 23, 2026
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 3, 2026
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
November 23, 2025
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
November 4, 2025
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
November 3, 2025
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
October 23, 2025
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
October 20, 2025
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
September 30, 2025
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
September 7, 2025
Sionna Therapeutics to Participate in Upcoming September Investor Conferences
August 26, 2025
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
August 24, 2025
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
August 10, 2025
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
June 5, 2025
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
June 3, 2025
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
May 21, 2025
Sionna Therapeutics Reports First Quarter 2025 Financial Results
May 11, 2025
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
April 29, 2025
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
March 19, 2025
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
February 23, 2025
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2025